Medivir Financial Statement, 1 January -- 31 December 2004

Huddinge, SWEDEN


HUDDINGE, Sweden, Feb. 18, 2005 (PRIMEZONE) -- Medivir's new issue was fully subscribed in June, raising the company SEK 322.5 m before deducting issue costs.

- In July, Medivir and Biovitrum entered a research collaboration on type 2 diabetes.

- In late November, Medivir signed a licensing and collaboration agreement in the hepatitis C (protease) segment with Tibotec Pharmaceuticals Ltd., a Johnson & Johnson group company.

- GSK (GlaxoSmithKline) concluded its research collaboration with Medivir on the HIV compound MIV-210 in late December. Medivir will now take this project onwards in phase IIa studies.

- Net sales in the Group amounted to SEK 82.6 m (previous year SEK 63.9 m excluding CCS and SEK 149.0 m including CCS).

- The Group's operating profit amounted to SEK -125.0 (-112.3) m and the net profit after tax were SEK -110.5 m (previous year of SEK -40.3 m including gains of SEK 63.4 m from the divestiture of CCS). Earnings per share were SEK -10.29 (-4.69).

FOR MORE INFORMATION, PLEASE CONTACT Rein Piir, CFO and VP, Investor Relations: +46 (0)70 853 7292.

FORTHCOMING FINANCIAL INFORMATION

The Three-month Interim Report will be published on 21 April 2005. The Annual General Meeting will be held on 21 April 2005, from 3 p.m. The Six-month Interim Report will be published on 7 July 2005. The Nine-month Interim Report will be published on 26 October 2005.

Medivir's financial reports are available from its Website, www.medivir.se from these dates, under the `Financial Information' heading.

The Medivir Group

Medivir is an innovative, specialist research corporation that develops drugs with the objective of becoming a sustaining, profitable pharmaceuticals corporation. Medivir is located in Huddinge, Sweden and near Cambridge, UK.

Medivir's research is oriented on developing new drug compounds based on polymerases and proteases as target enzymes. The group consists of Medivir AB, its subsidiary Medivir UK Ltd. and Medivir Personal AB. As of 31 December 2004, the group had 126 employees. Medivir was listed on the Stockholm Exchange O-list in 1996.

Medivir's research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, RA (rheumatoid arthritis), asthma and MS (multiple sclerosis). Medivir has five projects in clinical development phases, each with a unique clinical profile. The company's broad-based preclinical research portfolio houses six defined projects and nearly ten activities in various preclinical phases.

Medivir AB (publ), Lunastigen 7, 141 44 Huddinge, Sweden, tel (switchboard): +46 (0)8 546 83100

This information was brought to you by Waymaker http://www.waymaker.net

The following files are available for download:

http://wpy.waymaker.net/client/waymaker1/WOLReleaseFile.aspx?id=73854&fn=wkr0001.pdf

The full report


Tags